Atypical bartonellosis in children: What do we know?

被引:14
|
作者
Lemos, Ana P. [1 ]
Domingues, Rui [1 ]
Gouveia, Catarina [1 ]
de Sousa, Rita [2 ]
Brito, Maria J. [1 ]
机构
[1] Hosp Dona Estefania, Dept Infect Dis, Rua Jacinta Marto, P-1169045 Lisbon, Portugal
[2] Natl Inst Hlth Dr Ricardo Jorge, Ctr Study Vectors & Infect Dis, Lisbon, Portugal
基金
美国国家卫生研究院;
关键词
Bartonella infection; encephalitis; fever of unknown origin; lymphadenitis; osteomyelitis; retinitis; CAT-SCRATCH DISEASE; HENSELAE;
D O I
10.1111/jpc.15304
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim To characterise Bartonella infections in a paediatric population requiring hospital admission and review its treatment. Methods Longitudinal observational retrospective data analysis of children and adolescents admitted with Bartonella infection at a paediatric tertiary hospital from 2010 to 2019. Results We identified 16 cases of bartonellosis, with a mean age of 8.0 +/- 4.5 years old, no sex predominance and 14 had contact with cats. Most of the cases occurred in fall and winter. Clinical presentations included osteomyelitis/arthritis (n = 9), hepatosplenic disease (n = 2), lymphadenitis (n = 2), neuroretinitis (n = 2) and encephalitis (n = 1). Clinical diagnosis was confirmed by serology (n = 16) and Bartonella DNA detection in patient's lymph nodes/hepatic lesion (n = 3). Therapeutic approach varied according to the clinical presentation: azithromycin in lymphadenitis, rifampicin plus ciprofloxacin in hepatosplenic disease, rifampicin and doxycycline in neuroretinitis, ceftriaxone in encephalitis and azithromycin, cotrimoxazole or rifampicin plus azithromycin, cefuroxime, ciprofloxacin or doxycycline in osteomyelitis/arthritis. Immunodeficiency was excluded in seven patients. Seven patients' cats were screened by veterinarians and treated when infected (n = 5). Conclusions In these clinical presentations, where other infections may be involved, a high index of suspicion is necessary, with emphasis on the epidemiological context. The association of systemic forms with immunodeficiency did not occur in our study. The lack of recommendations for treatment of atypical infection makes the approach of these cases a challenge. Randomised control studies are essential to define the best approach in each case.
引用
收藏
页码:653 / 658
页数:6
相关论文
共 50 条
  • [21] What do we know, what do we need to know and how do we apply it?
    Lawrence, G.
    RADIOTHERAPY AND ONCOLOGY, 2007, 84 : S37 - S37
  • [22] Chronic prostatitis: what we know, what we do not know, and what we should do!
    Lobel, B
    Rodriguez, A
    WORLD JOURNAL OF UROLOGY, 2003, 21 (02) : 57 - 63
  • [23] WHAT DO WE KNOW, AND WHAT SHOULD WE KNOW?
    Flume, Patrick A.
    PEDIATRIC PULMONOLOGY, 2009, : 144 - 145
  • [24] Long COVID in Children: What Do We Know?
    Wadhwa, Anupma
    AMERICAN FAMILY PHYSICIAN, 2022, 106 (05) : 488 - 489
  • [25] Chronic prostatitis: what we know, what we do not know, and what we should do!
    B. Lobel
    A. Rodriguez
    World Journal of Urology, 2003, 21 : 57 - 63
  • [26] Participation of children with autism: What do we know?
    Askari, S.
    Anaby, D.
    Bergthorson, M.
    Majnemer, A.
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 2015, 47 : 98 - 98
  • [27] Asthma and obesity in children: what do we know?
    Novik, G. A.
    Khaleva, E. G.
    Makarova, S. G.
    Zhdanova, M., V
    BYULLETEN SIBIRSKOY MEDITSINY, 2019, 18 (03): : 183 - 191
  • [28] How Do We "Know" What We "Know?" And Change What We "Know?"
    Fosshage, James L.
    PSYCHOANALYTIC DIALOGUES, 2011, 21 (01) : 55 - 74
  • [29] BRCA1: What do we know? What do we think we know? What do we really need to know?
    Buller, RE
    GYNECOLOGIC ONCOLOGY, 2000, 76 (03) : 291 - 293
  • [30] Do we know what we test and do we test what we want to know?
    Klugkist, Irene
    van Wesel, Floryt
    Bullens, Jessie
    INTERNATIONAL JOURNAL OF BEHAVIORAL DEVELOPMENT, 2011, 35 (06) : 550 - 560